ADC Therapeutics S.A. (ADCT) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	78.8M	81.4M	70.8M	69.6M	209.9M
Cost of Revenue	8.9M	7.7M	5.9M	2.5M	3.3M
Gross Profit	69.9M	73.7M	64.9M	67.0M	206.6M
Operating Expenses
R&D Expense	82.2M	104.0M	109.6M	127.1M	186.5M
SG&A Expense	85.3M	(6.8M)	85.9M	105.9M	143.5M
General & Admin Expense	49.2M	36.6M	64.5M	72.9M	107.7M
Selling & Marketing Expense	36.1M	(43.4M)	21.4M	33.0M	35.8M
Other Expenses	1.4M	84.9M	—	—	—
Total Operating Expenses	169.0M	182.1M	195.5M	233.0M	330.0M
Cost and Expenses	177.9M	189.7M	201.5M	235.5M	333.3M
Operating Income (EBIT)	(99.1M)	(108.4M)	(130.7M)	(166.0M)	(123.3M)
Non-Operating
Interest Income	8.6M	8.8M	12.3M	10.5M	2.6M
Interest Expense	52.3M	51.6M	50.2M	46.3M	36.7M
Net Interest Income	(43.6M)	(42.8M)	(37.9M)	(35.8M)	(34.2M)
Other Non-Op Income/Expense	1.8M	(34.4M)	(27.0M)	(35.0M)	(33.6M)
Non-Operating Income (excl Interest)	(11.2M)	(17.2M)	(24.7M)	(16.9M)	(13.3M)
EBT (Pre-Tax Income)	(97.3M)	(142.8M)	(157.7M)	(200.9M)	(156.9M)
Income Tax Expense	(404.0K)	(157.0K)	166.0K	39.1M	227.0K
Bottom Line
Net Income	(96.9M)	(142.6M)	(157.8M)	(240.1M)	(157.1M)
Earnings from Cont. Ops	(96.9M)	(142.6M)	(157.8M)	(240.1M)	(157.1M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(96.9M)	(142.6M)	(157.8M)	(240.1M)	(157.1M)
Per Share
Basic EPS	($0.66)	($1.12)	($1.62)	($2.94)	($1.99)
Diluted EPS	($0.66)	($1.12)	($1.62)	($2.94)	($1.99)
Revenue Per Share	$0.51	$0.64	$0.73	$0.85	$2.69
Shares
Basic Shares Outstanding	155.0M	127.1M	97.2M	81.7M	78.2M
Diluted Shares Outstanding	155.0M	127.1M	97.2M	81.7M	78.2M
Profitability Metrics
EBITDA	(87.5M)	(89.3M)	(102.6M)	(145.8M)	(107.7M)
D&A	460.0K	1.9M	3.3M	3.3M	2.4M
EBIT	(87.9M)	(91.1M)	(105.9M)	(149.1M)	(110.1M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026